
A Nature Medicine paper by researchers from the Dana-Farber Cancer Institute, NYU and others features the discovery of a new genetic profile, SPARCS that predicts tumor immune response. The authors used AIM chips and human NSCLC biopsies to show that SPARCS_high profiles correspond with positive immune-checkpoint responses.